Vertex Pharmaceuticals (VRTX) Given Daily News Sentiment Rating of 0.16

News stories about Vertex Pharmaceuticals (NASDAQ:VRTX) have trended somewhat positive recently, according to Accern Sentiment. The research group identifies positive and negative media coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Vertex Pharmaceuticals earned a news impact score of 0.16 on Accern’s scale. Accern also assigned media stories about the pharmaceutical company an impact score of 46.268121118435 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.

These are some of the media stories that may have effected Accern Sentiment Analysis’s scoring:

Vertex Pharmaceuticals (NASDAQ VRTX) traded up $3.33 during midday trading on Friday, reaching $145.86. 3,210,391 shares of the company’s stock traded hands, compared to its average volume of 1,382,940. The company has a quick ratio of 3.14, a current ratio of 3.28 and a debt-to-equity ratio of 0.01. Vertex Pharmaceuticals has a fifty-two week low of $71.46 and a fifty-two week high of $167.85. The stock has a market capitalization of $36,046.23, a price-to-earnings ratio of 237.55, a P/E/G ratio of 3.41 and a beta of 1.58.

Vertex Pharmaceuticals (NASDAQ:VRTX) last released its quarterly earnings results on Wednesday, October 25th. The pharmaceutical company reported $0.53 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.04 by $0.49. Vertex Pharmaceuticals had a net margin of 8.53% and a return on equity of 9.23%. The business had revenue of $578.20 million for the quarter, compared to analyst estimates of $522.07 million. During the same period in the previous year, the company earned $0.16 earnings per share. The business’s revenue for the quarter was up 39.7% on a year-over-year basis. analysts forecast that Vertex Pharmaceuticals will post 0.76 EPS for the current year.

A number of brokerages have recently weighed in on VRTX. Vetr lowered Vertex Pharmaceuticals from a “strong-buy” rating to a “buy” rating and set a $181.00 price objective for the company. in a research report on Monday, September 4th. Royal Bank of Canada lifted their price target on Vertex Pharmaceuticals from $175.00 to $181.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 18th. Needham & Company LLC reiterated a “buy” rating and issued a $195.00 price target on shares of Vertex Pharmaceuticals in a research report on Sunday, September 17th. Zacks Investment Research lowered Vertex Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, October 24th. Finally, DA Davidson began coverage on Vertex Pharmaceuticals in a research report on Friday, September 29th. They issued a “buy” rating and a $200.00 price target for the company. One research analyst has rated the stock with a sell rating, five have issued a hold rating and twenty-four have issued a buy rating to the company. The company currently has a consensus rating of “Buy” and an average target price of $173.22.

In other news, CEO Jeffrey M. Leiden sold 125,000 shares of the business’s stock in a transaction on Monday, December 11th. The shares were sold at an average price of $141.35, for a total transaction of $17,668,750.00. Following the sale, the chief executive officer now directly owns 237,407 shares of the company’s stock, valued at $33,557,479.45. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CMO Jeffrey Chodakewitz sold 3,437 shares of the business’s stock in a transaction on Monday, October 2nd. The shares were sold at an average price of $151.64, for a total transaction of $521,186.68. The disclosure for this sale can be found here. Insiders sold 343,519 shares of company stock worth $49,488,660 over the last ninety days. Corporate insiders own 1.80% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Vertex Pharmaceuticals (VRTX) Given Daily News Sentiment Rating of 0.16” was originally published by Sports Perspectives and is the property of of Sports Perspectives. If you are viewing this piece on another publication, it was copied illegally and republished in violation of US and international trademark & copyright legislation. The original version of this piece can be read at https://sportsperspectives.com/2017/12/16/vertex-pharmaceuticals-vrtx-given-daily-news-sentiment-rating-of-0-16.html.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications.

Insider Buying and Selling by Quarter for Vertex Pharmaceuticals (NASDAQ:VRTX)

Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply